UK’s NICE Says No To AstraZeneca’s Evusheld Amid ‘Rapidly Changing’ COVID-19 landscape

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.

NICE says another no to AstraZeneca's Evusheld

Using AstraZeneca’s Evusheld (tixagevimab plus cilgavimab) as a preventative treatment for COVID-19 would likely be an unacceptable use of National Health Service resources and it is unclear if the product is effective against current variants of the virus, says new draft guidance from NICE, the health technology appraisal institute for England and Wales.

NICE also announced that it was developing a new review process involving real-world data for updating recommendations on the cost-effectiveness...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United Kingdom

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 
• By Eliza Slawther

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 
• By Eliza Slawther

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

Leqembi's UK Rollercoaster: A Yes From MHRA, A No From NICE

 
• By Neena Brizmohun

While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.

Working With The Inspectors: UK’s eXmoor Gets License To Make ATMPs

 
• By Eliza Slawther

It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 
• By Neena Brizmohun

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.